News & Updates

Real-world data reflect promising efficacy, safety of ozanimod for UC

30 Jan 2022 by

The first-in-class sphingosine-1-phosphate receptor modulator ozanimod showed promising efficacy and safety in a relatively treatment-refractory cohort of patients with ulcerative colitis (UC), according to the initial results of a prospective, observational cohort study presented at the Crohn’s and Colitis Congress 2022.

Real-world data reflect promising efficacy, safety of ozanimod for UC

30 Jan 2022

4th shot of COVID vaccine: Is it worthwhile?

29 Jan 2022 by

While a fourth dose of the COVID-19 vaccine boosts antibodies to levels that are higher than the third dose, it is not enough to protect against Omicron infections, according to preliminary data from Israel.

4th shot of COVID vaccine: Is it worthwhile?

29 Jan 2022

Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia

29 Jan 2022 by

Treatment with a single-pill combination (SPC) drug, composed of olmesartan and amlodipine, plus a separate dose of rosuvastatin led to significantly reduced systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) levels in patients with concomitant hypertension and dyslipidaemia, according to the LEISURE* trial.

Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia

29 Jan 2022

Erenumab effective for migraine regardless of aura status

28 Jan 2022 by

In a post hoc analysis, use of the anti-CGRP* receptor monoclonal antibody erenumab led to reduced migraine frequency and AMSM** days in individuals with migraine with and without a history of aura.

Erenumab effective for migraine regardless of aura status

28 Jan 2022

Dronedarone better than sotalol in post-AF ablation setting

27 Jan 2022 by

Treatment with dronedarone following atrial fibrillation (AF) ablation appears to lead to a reduced risk of cardiovascular hospitalization as well as lower rates of combined proarrhythmia when compared with sotalol, as shown in a recent study.

Dronedarone better than sotalol in post-AF ablation setting

27 Jan 2022

Menopausal hormone therapy carries increased cutaneous melanoma risk

27 Jan 2022

The use of unopposed oestrogen in menopausal women may contribute to a heightened risk of cutaneous melanoma, a study has found.

Menopausal hormone therapy carries increased cutaneous melanoma risk

27 Jan 2022

Early 3-day remdesivir course may prevent COVID-19 hospitalization, death

26 Jan 2022 by

An early, 3-day regimen of remdesivir may prevent hospitalization and death in patients with COVID-19 who are at risk for disease progression, according to results of the PINETREE study.

Early 3-day remdesivir course may prevent COVID-19 hospitalization, death

26 Jan 2022

Obsessive-compulsive symptoms in clozapine-treated patients take a toll on their wellbeing

26 Jan 2022

Obsessive-compulsive symptoms appear to frequently occur among schizophrenic patients receiving treatment with clozapine, and these symptoms exert a negative effect on the patients’ wellbeing, a study reports.

Obsessive-compulsive symptoms in clozapine-treated patients take a toll on their wellbeing

26 Jan 2022

Mirikizumab improves disease, symptom severity in patients with Crohn’s disease

26 Jan 2022 by

Treatment with the anti-interleukin-23p19 inhibitor mirikizumab led to significant improvements in patient-assessed disease severity and activity, as well as abdominal pain, in individuals with moderate-to-severe active Crohn’s disease, according to phase II data presented at the Crohn’s and Colitis Congress (CCC) 2022.

Mirikizumab improves disease, symptom severity in patients with Crohn’s disease

26 Jan 2022

Second-line tisagenlecleucel renders no EFS benefit in aggressive B-cell lymphoma

25 Jan 2022 by

The anti-CD19 chimeric antigen receptor (CAR) T-cell treatment tisagenlecleucel did not improve event-free survival (EFS) compared with standard care in patients refractory or who had progressed following first-line therapy for aggressive B-cell non-Hodgkin’s lymphoma, results of the phase III BELINDA trial showed.

Second-line tisagenlecleucel renders no EFS benefit in aggressive B-cell lymphoma

25 Jan 2022

News & Updates

Filter by Specialty:

Specialty:

Real-world data reflect promising efficacy, safety of ozanimod for UC

Real-world data reflect promising efficacy, safety of ozanimod for UC

4th shot of COVID vaccine: Is it worthwhile?

4th shot of COVID vaccine: Is it worthwhile?

Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia

Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia

Erenumab effective for migraine regardless of aura status

Erenumab effective for migraine regardless of aura status

Dronedarone better than sotalol in post-AF ablation setting

Dronedarone better than sotalol in post-AF ablation setting

Menopausal hormone therapy carries increased cutaneous melanoma risk

Menopausal hormone therapy carries increased cutaneous melanoma risk

Early 3-day remdesivir course may prevent COVID-19 hospitalization, death

Early 3-day remdesivir course may prevent COVID-19 hospitalization, death

Obsessive-compulsive symptoms in clozapine-treated patients take a toll on their wellbeing

Obsessive-compulsive symptoms in clozapine-treated patients take a toll on their wellbeing

Mirikizumab improves disease, symptom severity in patients with Crohn’s disease

Mirikizumab improves disease, symptom severity in patients with Crohn’s disease

Second-line tisagenlecleucel renders no EFS benefit in aggressive B-cell lymphoma

Second-line tisagenlecleucel renders no EFS benefit in aggressive B-cell lymphoma